On June 16, 2017, having completed its demerger from Actlion Ltd, Idorsia Ltd commenced trading on SIX Swiss Exchange. On its first day of trading, the shares of Idorsia Ltd opened at a price of CHF 10.00.
Idorsia is an independent biopharmaceutical company specialized in the discovery, development and commercialization of small molecule therapeutics to meet significant unmet medical needs. It is based in Allschwil, Switzerland and has over 600 employees.
In addition to its role as lead counsel to Actelion in the USD 30 billion public tender offer by Johnson & Johnson, NKF also acted as lead counsel to Idorsia in its demerger and listing on SIX. The NKF Team comprised partners Philipp Haas and Ulysses von Salis, senior associates Christina Del Vecchio and Moritz Maurer, associates Deirdre Ni Annrachain, Julia Tolstova and Samuel Hochstrasser, and junior associate Alexander Göbel.